Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
Dr. Reddy’s Laboratories (RDY) reported interim results for the quarter and six months ended September 30, 2025. Six‑month revenues were Rs. 173,503 million with profit of Rs. 28,364 million; basic EPS was Rs. 34.30. For the quarter, revenues were Rs. 88,051 million and profit was Rs. 14,268 million.
Gross profit for six months reached Rs. 96,767 million against operating expenses of Rs. 61,779 million, yielding operating profit of Rs. 34,988 million. The effective tax rate was 24.2% for six months. Operating cash flow was Rs. 30,202 million; cash and cash equivalents stood at Rs. 9,906 million with other investments of Rs. 64,487 million.
By segment (six months), Global Generics delivered Rs. 154,118 million revenue; PSAI contributed Rs. 17,631 million. By geography, revenues were United States Rs. 69,958 million, India Rs. 31,781 million, Russia Rs. 15,829 million, and Others Rs. 55,935 million. The balance sheet showed total assets Rs. 542,005 million, equity Rs. 362,082 million, short‑term borrowings Rs. 41,155 million and long‑term borrowings Rs. 17,384 million. The company paid a dividend of Rs. 6,659 million and recorded inventory write‑downs of Rs. 3,450 million over six months.